Faricimab is a bispecific antibody that targets two distinct pathways – via angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A) – that drive a number of retinal conditions ...

An add-on agent designed to boost drugs that treat age-related macular degeneration failed to show any benefit in two phase 3 ...

Ireland has become the first country to recruit patients onto a new global clinical trial into a potential treatment for a ...

In its guidance, NICE said that clinical data suggests Lytenava is more effective than ranibizumab as a treatment for wet AMD, and offers similar efficacy to aflibercept and faricimab. It also ...

UBX1325 is a novel BCL-xL inhibitor designed to eliminate senescent cells in diabetic retinal blood vessels, while leaving healthy ones intact. After review by the Data and Safety Monitoring Board, ...

为了寻找更有效的治疗方案，减轻患者的治疗负担，英国阿伯丁皇家医院眼科的研究人员 Maria A. Bantounou、Mohammed Elsheikh 等人开展了一项关于玻璃体内注射法瑞西单抗（faricimab）治疗 nAMD 的研究。该研究成果发表在《BMC Ophthalmology》杂志上，为 nAMD 的治疗提供了新 ...

A year ago, a new head of Social Security set out to stop the agency from financially devastating many of the people it was meant to help. The agency had long made it a practice to reduce or halt ...

Despite having higher rates of diabetes and diabetes-related complications, Black, Hispanic, and Indigenous individuals are significantly underrepresented in clinical trial research. Diabetes care isn ...